دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Aims+Scope/Editorial Board/Publication information
doi : 10.1016/S0167-8140(23)00146-9
Volume 181, April 2023, 109608
An ESTRO-ACROP guideline on quality assurance and medical physics commissioning of online MRI guided radiotherapy systems based on a consensus expert opinion
Stephanie Tanadini-Lang a,⇑, Geoff Budgell b , Omar Bohoudi c , Stefanie Corradini d , Davide Cusumano e,f , Görkem Güngör l , Linda G.W. Kerkmeijer g , Faisal Mahmood h,i , Simeon Nill j , Miguel A. Palacios c , Michael Reiner d , Daniela Thorwarth k , Lotte Wilke a , Jochem Wolthaus
doi : 10.1016/j.radonc.2023.109504
Volume 181, April 2023, 109504
18F-FDG-PET guided vs whole tumour radiotherapy dose escalation in patients with locally advanced non-small cell lung cancer (PET-Boost): Results from a randomised clinical trial
Saskia A. Cooke a,⇑, Dirk de Ruysscher b , Bart Reymen b , Maarten Lambrecht c,d , Gitte Fredberg Persson e,f,g , Corinne Faivre-Finn h , Edith M.T. Dieleman i , Rolf Lewensohn j,k , Judi N.A. van Diessen a , Karolina Sikorska l , Ferry Lalezari m , Wouter Vogel a,n , Wouter van Elmpt b , Eugène M.F. Damen a , Jan-Jakob Sonke a , José S.A. Belderbos
doi : 10.1016/j.radonc.2023.109492
Volume 181, April 2023, 109492
We aimed to assess if radiation dose escalation to either the whole primary tumour, or to an 18F-FDG-PET defined subvolume within the primary tumour known to be at high risk of local relapse, could improve local control in patients with locally advanced non-small-cell lung cancer.
Feasibility of omitting the clinical target volume under PET-CT guidance in unresectable stage III non-small-cell lung cancer: A phase II clinical trial
Tianxiang Cui a,1 , Anmei Zhang a,1 , Jianxiong Cui a,c , Lu Chen a , Guangpeng Chen a , Hongya Dai a , Xianli Qin b , Guanghui Li a,⇑, Jianguo Sun
doi : 10.1016/j.radonc.2023.109505
Volume 181, April 2023, 109505
Two-fraction stereotactic ablative radiotherapy with simultaneous boost to MRI-defined dominant intra-prostatic lesion – Results from the 2SMART phase 2 trial
Wee Loon Ong a,b,c , Patrick Cheung a,b , Hans Chung a,b , William Chu a,b , Jay Detsky a,b , Stanley Liu a,b , Gerard Morton a,b , Ewa Szumacher a,b , Chia-Lin Tseng a,b , Danny Vesprini a,b , Melanie Davidson a,b , Ananth Ravi b,d , Merrylee McGuffin a,b , Liying Zhang a , Alexandre Mamedov a , Andrea Deabreu a , Meghan Kulasingham-Poon a , Andrew Loblaw
doi : 10.1016/j.radonc.2023.109503
Volume 181, April 2023, 109503
This is the first report of the 2SMART Phase II trial evaluating the safety of two-fraction stereotactic ablative radiotherapy (SABR) with focal boost to magnetic resonance imaging (MRI) defined dominant intra-prostatic lesion (DIL) for localised prostate cancer.
Dose-escalated re-irradiation improves outcome in locally recurrent head and neck cancer – Results of a large multicenter analysis
Johannes Roesch a,b,c,⇑, Michael Oertel d , Simone Wegen e , Maike Trommer e,f , Julia Schleifenbaum e , Dominik Hering d , Matthias Mäurer g , Stefan Knippen g , Sophie Dobiasch h , Maria Waltenberger h , Jens von der Grün i , Daniel Medenwald j , Christoph Süß k , Michael Hoeck l , Lukas Käsmann m , Daniel F. Fleischmann m,n,o , Alexander Rühle p , Nils H. Nicolay p , Alexander Fabian q , Anastassia Löser r , Sebastian Heß s , Bálint Tamaskovics t , Maria Vinsensia u , Markus Hecht v , on behalf of Young DEGRO Group
doi : 10.1016/j.radonc.2022.10.007
Volume 181, April 2023, 109380
To determine efficacy and prognostic parameters of definitive re-irradiation of locoregionally recurrent squamous cell carcinoma of the head and neck (HNSCC).
Pseudoprogression in GBM versus true progression in patients with glioblastoma: A multiapproach analysis
Ingrid Sidibe a,b , Fatima Tensaouti a,b , Julia Gilhodes c , Bastien Cabarrou c , Thomas Filleron c , Franck Desmoulin b , Soleakhena Ken a,d , Georges Noël e , Gilles Truc f , Marie Pierre Sunyach g , Marie Charissoux h , Nicolas Magné i , Jean-Albert Lotterie b , Margaux Roques b , Patrice Péran b , Elizabeth Cohen-Jonathan Moyal a,d , Anne Laprie a,b,⇑
doi : 10.1016/j.radonc.2023.109486
Volume 181, April 2023, 109486
To investigate the feasibility of using a multiapproach analysis combining clinical data, diffusion- and perfusion-weighted imaging, and 3D magnetic resonance spectroscopic imaging to distinguish true tumor progression (TP) from pseudoprogression (PSP) in patients with glioblastoma.
Feasibility of clinical target volume reduction for glioblastoma treated with standard chemoradiation based on patterns of failure analysis
Giuseppe Minniti a,b,⇑, Paolo Tini a , Martina Giraffa c , Luca Capone c , Giorgio Raza c , Ivana Russo d , Elisa Cinelli a , PierCarlo Gentile c , Alessandro Bozzao e , Sergio Paolini b , Vincenzo Esposito
doi : 10.1016/j.radonc.2022.11.024
Volume 181, April 2023, 109435
To analyze recurrence patterns in patients with glioblastoma (GBM) after standard chemoradiation according to different target volume delineation strategies.
Dosimetric predictive factors for facial nerve paralysis after cyberknife® stereotactic radiotherapy for vestibular schwannomas: A single institution experience of 88 patients
William Gehin a,⇑, Benoîte Lassalle b , Julia Salleron a , René Anxionnat c , Didier Peiffert a , Vincent Marchesi a , Valérie Bernier-Chastagner
doi : 10.1016/j.radonc.2023.109519
Volume 181, April 2023, 109519
To identify dosimetric predictive factors of facial nerve paralysis for patients with vestibular schwannomas (VS) treated in a single institution with Cyberknife® (CK) hypofractionated stereotactic radiotherapy (SRT).
Association of persistent morbidity after radiotherapy with quality of life in locally advanced cervical cancer survivors
Sofia Spampinato a,⇑, Kari Tanderup a,b , Jacob C. Lindegaard c , Maximilian P. Schmid d , Alina Sturdza d , Barbara Segedin e,f , Ina M. Jürgenliemk-Schulz g , Astrid De Leeuw g , Kjersti Bruheim h , Umesh Mahantshetty i , Cyrus Chargari j , Bhavana Rai k , Rachel Cooper l , Elzbieta van der Steen-Banasik m , Marit Sundset n , Ericka Wiebe o , Elena Villafranca p , Erik Van Limbergen q , Bradley R. Pieters r,s , Li Tee Tan t , Ludy C.H.W. Lutgens u , Peter Hoskin v , Stéphanie Smet w , Richard Pötter d , Remi Nout x , Supriya Chopra y , Kathrin Kirchheiner d , on behalf of the EMBRACE Collaborative Group
doi : 10.1016/j.radonc.2023.109501
Volume 181, April 2023, 109501
To quantify the association of persistent morbidity with different aspects of quality of life (QOL) in locally advanced cervical cancer (LACC) survivors.
Overcoming inter-observer planning variability in target volume contouring and dose planning for high-risk neuroblastoma – a European multicenter effort of the SIOPEN radiotherapy committee
Danny Jazmati a,b,c,⇑, Lorenzo Brualla b,c,e , Annemieke S Littooij f,g , Britta Webber h , Karin Dieckmann i , Geert O Janssens j,g , Thorsten Simon k , Mark N. Gaze l , Julien Merta a,b , Antonio Serrano m , Stefan Dietzsch n , Paul-Heinz Kramer b,c , Jörg Wulff b,c , Tom Boterberg o , Beate Timmermann
doi : 10.1016/j.radonc.2023.109464
Volume 181, April 2023, 109464
To establish an international quality standard for contouring and planning for high-risk neuroblastoma within the prospective High-Risk Neuroblastoma Study 2 of SIOP-Europe-Neuroblastoma (SIOPEN HR-NBL2), which includes a randomized question on dose escalation for residual disease.
Developing an AI-assisted planning pipeline for hippocampal avoidance whole brain radiotherapy
Chih-Yuan Lin a,b , Lin-Shan Chou c , Yuan-Hung Wu a,b,c,d , John S. Kuo e,f,g , Minesh P. Mehta h,i , An-Cheng Shiau a,j,k , Ji-An Liang k,l , Shih-Ming Hsu a,b,⇑, Ti-Hao Wang
doi : 10.1016/j.radonc.2023.109528
Volume 181, April 2023, 109528
Hippocampal avoidance whole brain radiotherapy (HA-WBRT) is effective for controlling disease and preserving neuro-cognitive function for brain metastases. However, contouring and planning of HA-WBRT is complex and time-consuming.
Translational study for stereotactic body radiotherapy against non-small cell lung cancer, including oligometastases, considering cancer stem-like cells enable predicting clinical outcome from in vitro data
Ryo Saga a,⇑,1 , Yusuke Matsuya b,c,1 , Hikari Sato a , Kazuki Hasegawa a , Hideki Obara d , Fumio Komai d , Hironori Yoshino a , Masahiko Aoki e , Yoichiro Hosokawa
doi : 10.1016/j.radonc.2022.109444
Volume 181, April 2023, 109444
Curative effects of stereotactic body radiotherapy (SBRT) for non-small cell lung cancer (NSCLC) have been evaluated using various biophysical models. Because such model parameters are empirically determined based on clinical experience, there is a large gap between in vitro and clinical studies.
DKK1 affects survival of patients with head and neck squamous cell carcinoma by inducing resistance to radiotherapy and immunotherapy
Xinyu Ye a , Jingwen Liu b , Rencui Quan b , Yi Lu a,⇑, Jian Zhang
doi : 10.1016/j.radonc.2023.109485
Volume 181, April 2023, 109485
Immune checkpoint inhibitors (ICIs) have been approved to treat various types of tumors, including head and neck squamous cell carcinoma (HNSC). However, most HNSC patients do not respond to ICIs.
The prognosis may not be determined with the use of some pre-treatment complete blood count values in patients with non-metastatic nasopharyngeal carcinoma
Cengiz Beyan a,⇑ Esin Beyan
doi : 10.1016/j.radonc.2023.109529
Volume 181, April 2023, 109529
In reply to the Letter to the Editor by Cengiz Beyan and Esin Beyan regarding Can the prognosis of individual patients with nasopharyngeal carcinoma be predicted using a routine blood test at admission?
Jing-Rong Mao a,b Kai-Qi Lan a,c Sai-lan Liu a,c Chen Liu b Si-Yi Xie a,c Su-Chen Li a,c Wen-Feng Ye b Xue-Song Sun a,c Hai-Qiang Mai a,c
doi : 10.1016/j.radonc.2023.109530
Volume 181, April 2023, 109530
RE: Venkatesulu et al. (Letter to the Editor)
Susannah G. Ellsworth a Radhe Mohan b Steven H. Lin
doi : 10.1016/j.radonc.2023.109490
Volume 181, April 2023, 109490
With regards to Ellsworth et al. on “Lymphocyte sparing normal tissue effects in the clinic LymphoTEC): A systematic review of dose constraint considerations to mitigate radiation-related lymphopenia in the era of immunotherapy�
BhanuPrasad Venkatesulu a,b,⇑ Prashanth Giridhar
doi : 10.1016/j.radonc.2023.109496
Volume 181, April 2023, 109496
In regard to Yao et al.
Sezin Yuce Sari ⇑ Ezgi Gurlek Gozde Yazici
doi : 10.1016/j.radonc.2023.109493
Volume 181, April 2023, 109493
Response to the letter by Dr Sari regarding the article “The feasibility of reduced-dose radiotherapy in childhood nasopharyngeal carcinoma with favorable response to neoadjuvant chemotherapy”
Ji-Jin Yao a,b Ya-Nan Jin b Wang-Jian Zhang c Hong-Yu Zhang b Liang-Ping Xia
doi : 10.1016/j.radonc.2023.109487
Volume 181, April 2023, 109487
